Zr-89 ImmunoPET: Physics and Dosimetry

Introduction

Zirconium-89 immunoPET is positron emission tomography built around the physics of a slow radionuclide matched to a slow drug. Antibodies circulate and accumulate over days, not minutes, so imaging them requires a positron emitter whose half-life survives that timescale — and Zr-89, with a physical half-life of 78.4 hours (3.27 days), is the nuclide that fits. ^{1, 3}

That single design choice cascades into everything else. The same long half-life that enables day-3 to day-7 imaging also means the patient stays radioactive for a week. The nuclear structure that gives Zr-89 a convenient half-life also gives it a low positron branching ratio and an intense 909 keV gamma ray that F-18 does not have. These are not footnotes — they change count statistics, quantification, dose calibrator setup, shielding, and staff radiation protection. ^{1, 4, 5}

This article walks through the decay physics of Zr-89, how it compares with the positron emitters a nuclear medicine department already knows, what the 909 keV prompt gamma does inside and outside the scanner, how immunoPET images are quantified, and what published dosimetry says about patient and staff dose. DRPS supports PET and nuclear medicine programs adopting new radionuclides through PET/CT and nuclear medicine physics and medical physics consulting across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

What is Zr-89 immunoPET?

ImmunoPET is PET imaging of a labeled biologic — most often a monoclonal antibody — used to visualize where a target antigen is expressed and where the drug goes in the body. When the label is Zr-89, the technique is usually written 89Zr-immuno-PET. The radionuclide is attached to the antibody through a chelator, the labeled antibody is injected, and the patient is imaged one or more times over the following days as the antibody distributes, binds its target, and clears from the blood pool. ³

The clinical appeal is direct. A companion imaging agent that reports on target expression or antibody biodistribution can help select patients for antibody or antibody–drug-conjugate therapy, confirm that a drug reaches its target, and support the development of new biologics. ^{3, 4} For the underlying isotope characteristics that make some radionuclides better suited to this than others, see our overview of common PET and radiopharmaceutical-therapy isotopes.

Why the half-life has to match the biology

The reason Zr-89 exists in the immunoPET conversation at all is a timing problem. Intact IgG antibodies have a blood residence measured in days and often do not reach peak tumor-to-background contrast until 3 to 6 days after injection. ^{3, 5} A radionuclide has to still be emitting when that contrast develops.

• F-18 has a half-life of about 110 minutes. After 24 hours — long before an antibody has localized — it has gone through roughly 13 half-lives and is essentially gone.
• Ga-68 is shorter still, at about 68 minutes.
• Zr-89, at 78.4 hours, is still emitting usefully a week later.

This is why F-18 FDG and Ga-68 tracers, which dominate routine PET, are the wrong tools for intact-antibody imaging, and why Zr-89 (along with I-124 and, for faster-clearing constructs, Cu-64) occupies the long-half-life niche. ^{1, 3}

Key Technical Principles

The decay scheme of Zr-89

Zr-89 decays to Y-89 by a combination of positron emission and electron capture. The features that matter for imaging and safety are: ^{1, 2, 6}

• Physical half-life: 78.4 hours (3.27 days).
• Positron branching ratio: approximately 22.7% — only about one decay in four produces a positron. The remaining ~77% proceed by electron capture.
• Mean positron energy: approximately 396 keV (maximum near 900 keV), which is low and gives a short positron range.
• Prompt gamma: a 909 keV gamma ray emitted in about 99% of decays.

Two of those numbers define the character of Zr-89 imaging. The low positron branching ratio means the useful signal — the 511 keV annihilation-photon pairs — is produced in only ~23% of decays, so the coincidence yield per becquerel is far below F-18's ~97%. The 909 keV prompt gamma, present in nearly every decay, is the dominant term for external dose and shielding and a complicating factor inside the scanner. ¹

How Zr-89 compares with other positron emitters

The table below places Zr-89 among positron emitters a PET program may encounter. Values are representative published figures and should be verified against current nuclear data (for example, the NNDC or LNHB decay tables) for any specific application. ^{1, 2, 6, 7}

Read across the Zr-89 row and the trade-off is clear: a long, antibody-friendly half-life and a low, resolution-friendly positron energy, paired with a low branching ratio (fewer counts) and a high-abundance high-energy gamma (dose and scanner-physics consequences). ¹

The 909 keV prompt gamma inside the scanner

A PET scanner assumes that the two photons defining a coincidence line are 511 keV annihilation photons. Zr-89's 909 keV gamma breaks that assumption in two ways. ¹

First, it is emitted essentially at the same instant as the positron and its annihilation. If the 909 keV photon is detected in coincidence with one of the 511 keV photons, the scanner can record a spurious ("prompt-gamma") coincidence along a line that does not pass through the true annihilation point. This is the mechanism Conti and Eriksson describe for non-pure positron emitters, and for several isotopes it degrades contrast and quantitative accuracy enough to require dedicated prompt-gamma correction. ¹

For Zr-89 specifically, the 909 keV energy sits well above the 511 keV photopeak, so a properly set energy window rejects most of these events directly — the direct photopeak contamination is more limited than for emitters with gammas near 511 keV. But the 909 keV photons still: ¹

• raise the singles rate, increasing random coincidences;
• add to detector dead time, reducing the effective sensitivity for true events; and
• contribute scatter into the energy window.

Combined with the low positron branching ratio, the practical result is that Zr-89 images are count-starved relative to F-18 and benefit from longer bed times, careful randoms and scatter correction, and reconstruction tuned for low statistics. This is why harmonized acquisition and reconstruction — the same discipline behind EARL-style SUV harmonization — matters even more for Zr-89 than for FDG.

Positron range and spatial resolution

There is an upside to the low positron energy. A lower-energy positron travels a shorter distance before it annihilates, so the annihilation occurs closer to the decaying atom and the blurring from positron range is smaller. Zr-89's mean positron energy of ~396 keV gives it a short positron range — comparable to F-18 and considerably better than high-energy emitters such as Ga-68 or I-124. ¹ For the same reason we discuss in PET spatial resolution and positron range, this means Zr-89's intrinsic resolution is not the limiting factor — count statistics usually are.

Chelation: attaching Zr-89 to a protein

Zr-89 is a metal and must be held on the antibody by a chelator. The workhorse is desferrioxamine (DFO), usually conjugated to the antibody through a bifunctional linker such as DFO-Bz-NCS. DFO binds Zr-89 rapidly at room temperature and near-neutral pH, which is gentle enough to preserve antibody integrity. ^{2, 5}

The known weakness is in vivo stability: DFO is hexadentate and does not fully saturate Zr-89's coordination sphere, so a fraction of Zr-89 can be released over days and, being osteophilic, deposits in bone — showing up as skeletal uptake that is an imaging artifact, not target binding. This has driven development of octadentate and other next-generation chelators intended to hold Zr-89 more tightly. ² Understanding that free-Zr-89 bone signal is a physics-and-chemistry artifact, not disease, is part of reading these studies correctly.

Clinical Impact

Zr-89 immunoPET turns a therapeutic antibody into an imaging probe, and that changes what a scan can answer. Instead of a snapshot of glucose metabolism, the study reports where a specific antigen is expressed and whether a specific drug reaches it. ^{3, 4}

A representative example is DLL3-targeted imaging in neuroendocrine cancers. In a first-in-human study of a Zr-89-labeled anti-DLL3 antibody, patients received 37–74 MBq and were imaged serially out to day 7, with strong tumor-specific uptake at days 3 and 7 and tumor uptake that tracked DLL3 expression measured on biopsy. ⁴ According to PubMed, that trial is reported by Tendler et al. in Lancet Oncology (2024). The same multi-day imaging pattern appears across Zr-89 antibody studies, from HER2 imaging with Zr-89-trastuzumab to immune-checkpoint and other targets. ^{3, 5}

For a nuclear medicine department, adopting Zr-89 immunoPET is not simply "another tracer." It brings:

• Multi-day patient scheduling — a single study may involve imaging sessions on day 1, day 3, and day 6.
• Low-count acquisitions — bed times and administered activity have to be chosen against the low branching ratio.
• A new radiation-safety profile — a long-lived, high-energy-gamma source in the department and in the patient for a week.
• New quantification questions — SUV and biodistribution measurements that must account for the physics above to be reliable.

Key Technical Principles: worked examples

Decay across a multi-day protocol

Activity decays according to the standard exponential law, with decay constant $\lambda =\ln 2/T_{1/2}$:

For imaging on day 5 (120 hours) after injection, the fraction of the injected Zr-89 still present from physical decay alone is:

So about 35% of the administered Zr-89 remains at day 5 — enough to image, but a reminder that late-timepoint studies are working with a fraction of the starting activity on top of the low branching ratio. By contrast, F-18 after 120 hours would retain a factor of roughly $e^{-(0.693/1.83)(120)}\approx 10^{-20}$ of its activity: physically nothing. This is the quantitative core of why the half-life must match the biology.

Order-of-magnitude patient effective dose

Effective dose scales with administered activity through a radionuclide- and agent-specific dose coefficient $e$ (mSv/MBq):

Published patient dosimetry for Zr-89-labeled antibodies reports an effective dose on the order of $e\approx 0.49\text{mSv/MBq}$, with the liver among the highest-dose organs (reported liver doses on the order of 1.4–1.8 mGy/MBq). ^{4, 5} For a typical administered activity of 37 MBq:

and for 74 MBq, roughly 36 mSv. These are order-of-magnitude figures for planning and consent discussions; every program should confirm the coefficient against the specific radiopharmaceutical, chelator, and patient population it uses, framed within the ICRP methodology for patient radiopharmaceutical dosimetry. ^{4, 5, 11}

Practical Optimization Tips

Set up the dose calibrator correctly

Dose calibrator response depends on the photon spectrum, and Zr-89's spectrum — dominated by the 909 keV gamma rather than 511 keV — is not the same as F-18. Use the manufacturer's Zr-89 dial setting or a validated calibration factor, and verify it; do not assume the F-18 setting applies. Confirm accuracy and linearity for Zr-89 as part of the dose calibrator quality control program, because measurement error is easy to introduce when a new nuclide is added to a device configured for others.

Choose acquisition parameters for low counts

Because coincidence yield per becquerel is low, plan for it:

• Use longer bed/frame times at later timepoints where activity has decayed.
• Ensure randoms and scatter corrections are appropriate for a non-pure emitter.
• Keep acquisition and reconstruction consistent across timepoints and across scanners so serial and multi-center comparisons are valid.
• Validate quantification with a Zr-89 source in a phantom before trusting SUVs clinically.

Read bone uptake critically

Skeletal uptake in a Zr-89 study may reflect released free Zr-89 from chelator instability rather than target expression. Correlate with the chelator used, the timepoint, and the expected biodistribution before interpreting bone signal as disease. ²

Plan the schedule around the half-life

Build the imaging protocol, hot-lab workflow, and patient scheduling around a source that persists for days. Coordinate delivery, calibration, and imaging slots so that decay and biology are both accounted for, and so staff exposure is managed across the full multi-day protocol.

Regulatory Considerations

Zr-89 is byproduct material, and its medical use falls under the same NRC or Agreement State framework as any other PET radionuclide. Possession and use are authorized under a radioactive material license, and the medical-use requirements of 10 CFR Part 35 apply, with occupational and public dose limits set by 10 CFR Part 20. ^{9, 10}

Several features of Zr-89 deserve specific attention in the radiation safety program:

• External dose rate and shielding. The 909 keV gamma is far more penetrating than 511 keV annihilation photons in the sense that it requires more shielding material per photon, and it is emitted in ~99% of decays. Even though administered activities are low (tens of MBq), the half-value layer in lead is larger for 909 keV, so hot-lab and storage shielding sized for F-18 should be reassessed rather than assumed adequate. ¹
• Occupational exposure over multi-day protocols. Because the patient remains a source for a week, imaging staff can accumulate dose across repeated sessions with the same patient. This should be reflected in the facility's occupational exposure monitoring and ALARA planning.
• Contamination and waste. The long half-life lengthens decay-in-storage timelines for contaminated materials and waste compared with short-lived PET nuclides.
• Program authorization. Adding a new radionuclide typically requires confirming license authorization, authorized-user training and experience, written directives where applicable, dose calibrator QC for the new nuclide, and updated procedures — coordinated with radioactive material license support and the RSO.

Facilities should confirm which authority issues their license. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that administer medical use under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. Program-specific guidance for medical-use licensees is in NUREG-1556, Volume 9. ^{9, 13}

Frequently Asked Questions (FAQs)

What is zirconium-89 immunoPET?

Zirconium-89 (Zr-89) immunoPET is positron emission tomography performed with a monoclonal antibody, antibody fragment, or other slow-clearing biologic labeled with the positron-emitting radionuclide Zr-89. Because Zr-89 has a 3.27-day physical half-life that matches the days-long circulation of antibodies, it lets clinicians image target expression and drug distribution several days after injection.

Why is Zr-89 used instead of F-18 for antibody imaging?

Antibodies take days to reach maximum tumor uptake and clear from blood, while F-18 (110-minute half-life) has decayed away long before then. Zr-89's 78.4-hour half-life is long enough to follow antibody pharmacokinetics over 3 to 7 days, making it well suited to immunoPET where F-18 and Ga-68 are not.

What is the significance of the 909 keV gamma from Zr-89?

Zr-89 emits a 909 keV gamma ray in about 99% of decays, in addition to the 511 keV annihilation photons used for PET. This high-energy prompt gamma raises the singles rate, randoms, and dead time in the scanner, dominates the external dose rate for shielding and staff protection, and must be considered in dose calibrator setup and quality control.

How much radiation dose does a Zr-89 immunoPET scan deliver?

Published patient dosimetry for Zr-89-labeled antibodies reports an effective dose on the order of roughly 0.4 to 0.6 mSv per MBq, with the liver typically among the highest-dose organs. For a common administered activity of 37 to 74 MBq, that corresponds to an effective dose on the order of 18 to 37 mSv, and each program should confirm values against its specific radiopharmaceutical and patient population.

Does Zr-89's low positron branching ratio hurt image quality?

Only about 23% of Zr-89 decays produce a positron, so the coincidence yield per becquerel is far lower than F-18. This means lower count statistics and noisier images unless imaging time, administered activity, or reconstruction is adjusted, but the low positron energy also gives good intrinsic spatial resolution.

What chelator is used to attach Zr-89 to an antibody?

The most widely used chelator for Zr-89 is desferrioxamine (DFO), typically conjugated to the antibody through a bifunctional linker such as DFO-Bz-NCS. DFO binds Zr-89 rapidly at room temperature, though in vivo release of free Zr-89 to bone has driven development of alternative chelators with greater stability.

How long does a patient remain a radiation source after Zr-89 imaging?

Because of the 3.27-day half-life and days-long biological retention, a patient injected with Zr-89 remains a measurable source for a week or more. This matters for repeat imaging sessions across several days, for occupational dose to imaging staff over multi-day protocols, and for any release or contamination considerations the radiation safety program addresses.

Key Takeaways

• The half-life is the whole point. Zr-89's 78.4-hour half-life matches the days-long pharmacokinetics of antibodies, enabling PET imaging at day 3 to day 7 when F-18 and Ga-68 have long since decayed. ^{1, 3}
• Low branching ratio, few counts. Only ~23% of Zr-89 decays yield a positron, so images are count-starved relative to F-18 and need longer acquisitions and careful correction. ¹
• The 909 keV gamma matters everywhere. Emitted in ~99% of decays, it raises randoms and dead time in the scanner and dominates external dose and shielding — even at low administered activities. ¹
• Good intrinsic resolution. The low positron energy gives a short positron range, so count statistics, not positron range, usually limit image quality. ¹
• Watch bone uptake. Skeletal signal may be released free Zr-89 from chelator instability, not target binding. ²
• Plan the safety program for a week-long source. Dose calibrator setup, shielding, occupational monitoring, and waste timelines all change relative to short-lived PET nuclides. ^{4, 5, 9}

Conclusion

Zr-89 immunoPET is one of the clearest cases in nuclear medicine where the physics of the radionuclide and the biology of the drug have to be understood together. The 3.27-day half-life is exactly what antibody imaging needs, and the price of that half-life — a low positron branching ratio and an intense 909 keV prompt gamma — is paid in count statistics, scanner physics, quantification, patient dose, and staff radiation safety.

A department that treats Zr-89 as "just another PET tracer" configured like F-18 will get noisy images, questionable SUVs, and an underestimated safety profile. A department that sets up the dose calibrator for Zr-89, tunes acquisition for low counts, reads bone uptake critically, and plans the radiation safety program around a week-long source will get quantitative immunoPET it can trust and defend.

How DRPS Can Help

Diagnostic Radiation Physics Services helps PET and nuclear medicine programs bring new radionuclides like Zr-89 online correctly. That support can include dose calibrator QC and dial-setting verification for the new nuclide, acquisition and reconstruction review for low-count imaging, phantom-based quantification validation, hot-lab and storage shielding reassessment, occupational dose and ALARA review, and license and authorized-user coordination — delivered through PET/CT and nuclear medicine physics, medical physics consulting, and radioactive material license support.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

Related Resources

• Common PET & RPT isotopes
• PET spatial resolution and positron range
• EARL PET SUV harmonization
• Dose calibrator quality control
• Cyclotron F-18 production
• Occupational exposure monitoring
• PET/CT and nuclear medicine physics
• Medical physicist consulting

References

1. Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Physics. 2016;3(1):8. doi:10.1186/s40658-016-0144-5. doi.org
2. Buchwalder C, Rodríguez-Rodríguez C, Schaffer P, et al. A new tetrapodal 3-hydroxy-4-pyridinone ligand for complexation of zirconium for positron emission tomography (PET) imaging. Dalton Transactions. 2017;46(29):9654-9663. doi:10.1039/c7dt02196h. doi.org
3. van Dongen GAMS, Beaino W, Windhorst AD, et al. The role of 89Zr-immuno-PET in navigating and derisking the development of biopharmaceuticals. Journal of Nuclear Medicine. 2021;62(4):438-445. doi:10.2967/jnumed.119.239558. doi.org
4. Tendler S, Dunphy MP, Agee M, et al. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. The Lancet Oncology. 2024;25(8):1015-1024. doi:10.1016/S1470-2045(24)00249-3. doi.org
5. O'Donoghue JA, Lewis JS, Pandit-Taskar N, et al. Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer. Journal of Nuclear Medicine. 2018;59(1):161-166. doi:10.2967/jnumed.117.194555. doi.org
6. Laboratoire National Henri Becquerel. Zr-89 decay data table. lnhb.fr
7. National Nuclear Data Center, Brookhaven National Laboratory. NuDat nuclear decay data for Zr-89. nndc.bnl.gov
8. National Institute of Standards and Technology. Radionuclide half-life measurements. nist.gov
9. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
10. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
11. International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals. Annals of the ICRP. 2015;44(2S). icrp.org
12. Tang Y, Hu Y, Liu W, et al. A radiopharmaceutical [89Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo. Nuclear Medicine and Biology. 2019;70:23-31. doi:10.1016/j.nucmedbio.2019.01.007. doi.org
13. U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Consolidated Guidance About Materials Licenses — Program-Specific Guidance About Medical Use Licenses. nrc.gov